New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.

New Long Position: Gene Therapy for Parkinson's Disease and Upcoming Catalysts

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>We listened to the conference call by <a href="https://www.smartkarma.com/entities/15201" target="_blank" data-smartkarma-citation="entities:15201:1">Ophthotech Corp (OPHT US)</a> management (<a href="http://edge.media-server.com/m/p/ta7q85as" target="_blank">link</a>). The results of the phase 3 trial were shocking to many investors since the phase 2b study showed a clear significant benefit for Fovista+Lucentis combination (with shorter duration of treatment). <a href="http://investors.ophthotech.com/releasedetail.cfm?ReleaseID=1003651" target="_blank">Link</a> to press release.</p><p>In the phase 3 study, the efficacy in the Fovista arm was similar to the phase 2b but the clinical efficacy in the Lucentis arm increased compared to phase 2b, resulting in non-significant benefit in…</p>

We listened to the conference call by Ophthotech Corp (OPHT US) management (link). The results of the phase 3 trial were shocking to many investors since the phase 2b study showed a clear significant benefit for Fovista+Lucentis combination (with shorter duration of treatment). Link to press release.In the phase 3 study, the efficacy in the Fovista arm was similar to the phase 2b but the clinical efficacy in the Lucentis arm increased compared to phase 2b, resulting in non-significant benefit in…

IVERIC bio

Ophthotech: What Is Next?